Comparing the Efficacy and Safety of Natalizumab and Ocrelizumab in Patients with Relapsing-Remitting Multiple Sclerosis and Spinal Lesions

被引：0
|
作者：
Huntemann, Niklas [1 ,2 ]
Mueller, Marc [1 ,2 ]
Masanneck, Lars [1 ,2 ]
Baumgart, Romy [3 ]
Axhausen, Franziska [3 ]
Wolff, Stephanie [3 ]
Kutsojannis, Bela [1 ,2 ]
Koelsche, Tristan [1 ,2 ]
Korsen, Melanie [1 ,2 ]
Pfeuffer, Steffen [3 ]
Meuth, Sven [1 ,2 ]
Pawlitzki, Marc [1 ,2 ]
机构：
[1] Heinrich Heine Univ Dusseldorf, Med Fac, Dept Neurol, Dusseldorf, Germany
[2] Heinrich Heine Univ Dusseldorf, Univ Hosp Dusseldorf, Dusseldorf, Germany
[3] Justus Liebig Univ Giessen, Univ Hosp Giessen & Marburg, Dept Neurol, Giessen, Germany
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
O095/1249
引用
收藏
页码：90 / 91
页数：2
相关论文
共 50 条
  • [31] Real world efficacy and safety of teriflunomide in patients with relapsing-remitting multiple sclerosis
    Boz, C.
    Ozakbas, S.
    Terzi, M.
    Turkoglu, R.
    Akman, G.
    Efendi, H.
    Akcali, A.
    Tuncer, A.
    Yuceyar, N.
    Turan, O. F.
    Soysal, A.
    Koseoglu, M.
    Balci, B. P.
    Sevim, S.
    Altintas, A.
    Cilingir, V.
    Demirkiran, M.
    Kizilay, F.
    Altunrende, B.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 327 - 328
  • [32] Ocrelizumab in Early-Stage Relapsing-Remitting Multiple Sclerosis
    Hartung, Hans-Peter
    Benedict, Ralph H. B.
    Berger, Thomas
    Bermel, Robert A.
    Brochet, Bruno
    Carroll, William M.
    Freedman, Mark S.
    Holmoy, Trygve
    Karabudak, Rana
    Nos, Carlos
    Patti, Francesco
    Perrin Ross, Amy
    Vanopdenbosch, Ludo
    Vollmer, Timothy
    Wuerfel, Jens
    Clinch, Susanne
    Kadner, Karen
    Kuenzel, Thomas
    Kulyk, Inessa
    Raposo, Catarina
    Thanei, Gian-Andrea
    Killestein, Joep
    NEUROLOGY, 2024, 103 (12)
  • [33] Half-dose ocrelizumab in selected patients with relapsing-remitting multiple sclerosis
    Algahtani, Hussein
    Shirah, Bader
    Alqahtani, Abdulhadi
    Abdelghaffar, Nawal
    Makki, Samiah
    ACTA NEUROLOGICA BELGICA, 2024, 124 (01) : 303 - 306
  • [34] Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
    Mansour A. Alharbi
    Fahad Aldosari
    Ahmed Hasan Althobaiti
    Faris M. Abdullah
    Salman Aljarallah
    Nuha M. Alkhawajah
    Miteb Alanazi
    Yazed AlRuthia
    BMC Health Services Research, 23
  • [35] Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
    Alharbi, Mansour A.
    Aldosari, Fahad
    Althobaiti, Ahmed Hasan
    Abdullah, Faris M.
    Aljarallah, Salman
    Alkhawajah, Nuha M.
    Alanazi, Miteb
    AlRuthia, Yazed
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [36] Evaluation of shorter infusion times with ocrelizumab in patients with relapsing-remitting multiple sclerosis
    Vollmer, Timothy
    Alvarez, Enrique
    Nair, Kavita
    Cohen, Jeffrey
    Boster, Aaron
    Masterman, Donna
    Pradhan, Ashish
    Musch, Bruno
    Ma, Xiaoye
    Pei, Jinglan
    Moss, Brandon
    Weinstock-Guttman, Bianca
    Bermel, Robert
    NEUROLOGY, 2019, 92 (15)
  • [37] Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study
    D'Amico, Emanuele
    Zanghi, Aurora
    Calogero, Aldo Eugenio
    Patti, Francesco
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (14) : 2284 - 2287
  • [38] Ocrelizumab and Cladribine have Similar Efficacy and Safety in Naive Relapsing Remitting Multiple Sclerosis Patients
    Alroughani, R.
    Al-Hashel, J.
    Ahmed, S. Farouk
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 97 - 97
  • [39] Predicting the response status to natalizumab in relapsing-remitting multiple sclerosis
    Prosperini, L.
    Mancinelli, C. R.
    Gianni, C.
    Barletta, V.
    Fubelli, F.
    Borriello, G.
    Pozzilli, C.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 469 - 470
  • [40] Natalizumab: A guide to its use in relapsing-remitting multiple sclerosis
    Keating G.M.
    McCormack P.L.
    Drugs & Therapy Perspectives, 2014, 30 (2) : 48 - 54
12345